Long COVID is an important issue

Dr. Stephen Quay discusses a recent study published in the European Journal of Radiology about “long COVID,” where patients experience ongoing symptoms post-recovery. The study, conducted in Wuhan, China, involved 141 patients with diabetes, hyperglycemia, or as a control group. CT scans at six and twelve months showed that 55% and 52% respectively had lung abnormalities, notably ground glass opacifications, often associated with viral pneumonias. These abnormalities were more prevalent in patients with pre-existing conditions and those hospitalized for over 20 days. For more details, the paper can be accessed online.

Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.

His current passion is the prevention of the two million yearly breast cancer cases worldwide.

Related Content

(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies